In 2016 the selective Bcl-2 inhibitor Venetoclax, which acts as a BH3-mimetic to facilitate the activation of pro-apoptotic Bcl-2 family members, was approved for relapsed/refractory CLL (7). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.